BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1385363)

  • 1. The current role of prostatic acid phosphatase and prostate-specific antigen in the management of prostate cancer.
    Shetty SD; Cerny JC
    Henry Ford Hosp Med J; 1992; 40(1-2):93-8. PubMed ID: 1385363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D; Kamil ST; Pakasi LS
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma.
    Chakrabarti S; Raha K; Bhunia CL; Bhattachary DK
    J Indian Med Assoc; 2001 Nov; 99(11):627-8, 630. PubMed ID: 12022203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
    Kamoi K; Babaian RJ
    Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
    Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
    Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
    de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
    Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of prostate-specific antigen (PSA) and PSA density in the detection of stage T1 carcinoma of the prostate.
    Presti JC; Carroll PR
    Semin Urol Oncol; 1996 Aug; 14(3):134-8. PubMed ID: 8865474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening.
    Roetzheim RG; Herold AH
    Prim Care; 1992 Sep; 19(3):637-49. PubMed ID: 1384077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?].
    Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU
    Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early management of prostate cancer: how to respond to an elevated PSA?
    Canto EI; Slawin KM
    Annu Rev Med; 2002; 53():355-68. PubMed ID: 11818479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The usefulness of prostate-specific antigen assay for the early detection and follow up of the prostate cancer].
    Saito Y
    Nihon Rinsho; 1998 Aug; 56(8):1989-93. PubMed ID: 9750493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.